Search the Newsreel

AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85%

6 Green Days In A Row: AbCellera Biologics Stock Is Up 85%

AbCellera Biologics (ABCL) stock has surged 85% over six consecutive trading days, reaching a new 52-week high and adding $1.5 billion to its market value. While its revenue growth is strong at 101.3% over the last twelve months, the company faces profitability challenges with …

AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031

This article provides price predictions for AbCellera Biologics Inc. • Robinhood Token (ABCL) from 2026 to 2045, based on Bybit AI's analysis of user-driven Consensus Ratings and historical patterns. It forecasts a positive trend for ABCL's price, with significant potential ROI over the years, …

AbCellera Biologics prices oversubscribed $200M offering at $9.75/share

AbCellera Biologics (ABCL [https://seekingalpha.com/symbol/ABCL]) announced the pricing of its oversubscribed underwritten public offering [https://seekingalpha.com/pr/20617674-abcellera-announces-pricing-of-oversubscribed-200-million-public-offering-of-common-shares] of 17.44M common shares at $9.75 per share. In lieu of common shares, AbCellera is also offering pre-funded warrants to purchase up to 3.08M common shares at $9.74999 per warrant …

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Chief Legal and Compliance Officer - Tryn Stimart President and Chief Executive Officer - Carl L. Hansen Chief Financial Officer - Andrew Booth Full Conference Call Transcript Operator: …

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - Here's Why

AbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of "Moderate Buy" by Analysts

AbCellera Biologics Inc. (NASDAQ:ABCL) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $12.83, notably boosted by Truist Financial's increased target of $30. The company's shares have rallied significantly following positive Phase 2 results for its experimental …

Revenue Downgrade: Here's What Analysts Forecast For AbCellera Biologics Inc. (NASDAQ:ABCL)

Analysts have recently downgraded their revenue forecasts for AbCellera Biologics Inc. for 2024 and 2025, suggesting a more cautious outlook on the company's near-term growth prospects. Despite the revised estimates, the average price target for ABCL stock remains unchanged, implying that analysts see potential …

ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL)

AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The latest analyst update on AbCellera Biologics reflects a higher Fair Value estimate of …

AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story

AbCellera stock falls on $200M public offering launch

AbCellera Biologics Inc. (NASDAQ:ABCL) shares dropped 3.7% after the company announced a $200 million underwritten public offering of common stock and pre-funded warrants. The biotechnology company intends to use the net proceeds to fund research, development, and clinical advancement of its internal pipeline, including …

Truist Financial Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price

AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 8.7% - Here's What Happened

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

AbCellera (Nasdaq: ABCL) is set to release top-line data from its Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026. The company will also host an investor conference call and webcast to discuss the results. …

AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook

AbCellera Biologics (ABCL) surged 44% to a three-year high following positive clinical trial results for its hot flash treatment, ABCL635. The drug significantly reduced hot flashes in postmenopausal women, outperforming a placebo, and analysts are bullish on its potential in a large addressable market. …

AbCellera stock soars on ‘off the chart’ trial results from hot flash treatment for menopausal women

AbCellera Biologics Inc. saw its stock soar after announcing "off the chart" human trial results for its hot flash treatment, ABCL635, which proved more effective and had fewer side effects than existing therapies. The drug, aimed at menopausal women and those undergoing hormone-suppressing cancer …

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera has announced positive top-line results from its Phase 2 clinical trial for ABCL635, an investigational antibody for treating moderate-to-severe vasomotor symptoms (hot flashes) in menopausal women. The study demonstrated statistically significant reductions in both the frequency and severity of symptoms, as well as …

AbCellera Biologics Sees Unusually High Options Volume (NASDAQ:ABCL)

AbCellera Biologics (NASDAQ:ABCL) experienced unusually high options trading volume, with investors purchasing 16,666 call options, a 151% increase over the average. The company's shares surged by $2.37 to $9.30 on heavy trading volume, despite missing analyst expectations for both earnings and revenue in its …

Abcellera Biologics stock hits 52-week high at 8.79 USD

Abcellera Biologics Inc. (ABCL) reached a 52-week high of $8.79, reflecting a 63% total return over the past year and 119% over six months. Despite this, an InvestingPro analysis suggests the stock may be overvalued. The company also announced positive Phase 2 clinical trial …

Why is Abcellera Biologics stock surging today?

Abcellera Biologics (ABCL) stock surged over 30% in pre-open trading after its antibody, ABCL 635, met the primary efficacy endpoint in a Phase 2 clinical trial for menopausal hot flashes, showing an 83% reduction in frequency. This clinical success, combined with strong analyst conviction …

AbCellera's ABCL635 Delivers Strong Phase 2 Data; Stock Jumps 33%

(RTTNews) - AbCellera Biologics Inc. (ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational NK3R antagonist antibody for moderate-to-severe vasomotor symptoms due to menopause. The study met its primary efficacy endpoints achieving statistically …

AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

AbCellera Biologics announced positive top-line results from its Phase II trial of ABCL-635, a non-hormonal treatment for menopausal hot flashes. The study showed an 83% reduction in moderate-to-severe hot flashes, along with improvements in symptom severity and sleep disturbance, and a favorable tolerability profile. …

ABCL Stock Rips As Vertex Deal And Data Catalyst Fire Up Traders

AbCellera Biologics Inc. (ABCL) stock surged over 24% due to strong optimism surrounding its antibody discovery platform, a new collaboration with Vertex Pharmaceuticals, and upcoming Phase 2 data for ABCL635. The Vertex deal provides $28 million upfront, with potential milestones and royalties, validating ABCL's …

AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Slashed This Year's Revenue Estimates By 22%

Analysts have significantly revised down AbCellera Biologics Inc.'s (NASDAQ:ABCL) revenue estimates for 2026 by 22%, now forecasting US$25 million, which represents a 62% decline year-over-year. Despite this pessimistic outlook, the company's share price has recently risen by 19%. The updated forecasts suggest AbCellera Biologics …

AbCellera To Present Phase 2 Results Of ABCL635 For Menopause Symptoms Today

(RTTNews) - AbCellera Biologics Inc. (ABCL) announced that it will release top-line results from its Phase 2 clinical trial from its Phase 2 clinical trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes due to menopause, before …

AbCellera Biologics (ABCL) Is Up 21.4% After First Phase 2 Readout For Novel NK3R Antibody – Has The Bull Case Changed?

AbCellera Biologics (ABCL) saw its stock rise 21.4% following the first Phase 2 readout for its novel NK3R antibody, ABCL635, targeting menopausal vasomotor symptoms. This marks a significant step in AbCellera's shift towards developing internal therapeutic programs, offering an early test of its new …

AbCellera (NASDAQ:ABCL) Shares Surge Ahead of Monday's ABCL635 Phase 2 Trial Results

AbCellera's shares surged ahead of the release of its ABCL635 Phase 2 trial results on Monday, with the stock gaining 9.7% in after-hours trading, adding an estimated $205 million to its market value. Despite recent quarterly revenue declines, the anticipation of clinical validation for …

AbCellera Biologics | 8-K: Current report

This document is an 8-K current report filed by AbCellera Biologics. The content of the report itself is not provided, only the fact that it is an 8-K filing.

AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate

AbCellera Biologics (ABCL) saw its stock jump 10.3% despite reporting a significant cash burn and widening net loss in Q2 2026. The market reaction is attributed to the company's substantial cash pile of US$567 million and over US$675 million in liquidity, which is being …

AbCellera Biologics Inc. $ABCL Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC significantly reduced its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 36.8% in the first quarter, selling 878,600 shares but still retaining 1.51 million shares valued at $5.27 million. This comes as AbCellera reported weaker-than-expected quarterly results, missing both earnings per share …

AbCellera Biologics Inc. Stock 12‑Month Price Target Raised to $10.75, Implies 82% Upside

AbCellera Biologics Inc. (ABCL) has seen its average 12-month price target raised to $10.75 by 8 analysts, up from $10.50, with individual forecasts ranging from $7 to $13. This updated target suggests an 82% potential upside based on the August 5th closing price. The …

Earnings call transcript: AbCellera misses Q2 2026 estimates as revenue drops

AbCellera Biologics Inc. reported a wider-than-expected Q2 2026 loss and revenue significantly below analyst estimates, with revenue dropping by 76% year-over-year. The company attributed the revenue decline to a strategic shift from external collaborations to internal drug development, leading to increased R&D spending. Despite …